Viewing Study NCT05334758


Ignite Creation Date: 2025-12-25 @ 12:14 AM
Ignite Modification Date: 2025-12-28 @ 3:05 AM
Study NCT ID: NCT05334758
Status: COMPLETED
Last Update Posted: 2024-03-12
First Post: 2022-04-15
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Clinical Performance Evaluation of the Bio-Self™ COVID-19 Antigen Home Test
Sponsor: BioTeke USA, LLC
Organization:

Study Overview

Official Title: Clinical Performance Evaluation of the Bio-Self™ COVID-19 Antigen Home Test
Status: COMPLETED
Status Verified Date: 2024-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to evaluate the performance of the Bio-Self COVID-19 Antigen Home Test. The study will evaluate the accuracy (sensitivity and specificity) in a simulated home use environment when compared to a high-sensitivity Emergency Use Authorization (EUA) SARS-CoV-2 RT-PCR assay.
Detailed Description: The Bio-Self COVID-19 Antigen Home Test is immunochromatographic and uses double-antibody sandwich method to detect SARS-CoV-2 antigen from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection. The test is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older or adult collected anterior nares swab samples from individuals ages 2 to 13.

The primary objective of this study is to determine the accuracy of the Bio-Self COVID-19 Antigen Home Test when compared to a high-sensitivity Emergency Use Authorization (EUA) SARS-CoV-2 RT-PCR assay.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: True
Is an Unapproved Device?: True
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: